CAR T CELL THERAPY
IN INDIA

CAR T (chimeric antigen receptor T cell) therapy is a form of immunotherapy that reprograms your own immune cells to recognize and destroy cancer cells. Unlike chemotherapy, it uses living cells that persist and multiply inside the body — often called a 'living drug.'

“A single CAR T infusion can keep working for months, and in some patients for years — something no chemotherapy regimen can replicate.”

• The Core Concept

  T cells are collected from the patient's blood, genetically reprogrammed in a lab with a chimeric antigen receptor (CAR), multiplied into millions, then infused back. The new receptor acts as a homing device pointing directly at cancer cells.

• What It Targets

  Most approved CAR T therapies target CD19 — a protein marker found on the surface of many B cell cancers. Both Indian approved products, NexCAR19 and Qartemi, are CD19-directed and used for B cell leukemias and lymphomas.

• Why It's Different

  Unlike chemotherapy given in repeated courses and cleared from the body, CAR T cells are alive. They multiply inside the patient, persist for extended periods, and can produce deep, lasting remissions not achievable with standard treatments.

• Who It's For

  CAR T is not a first-line treatment. It is reserved for patients whose cancer has relapsed after standard therapy or has stopped responding — typically after two or more prior treatment lines have failed.

CAR T is a process, not a single appointment. Understanding the full journey — from cell collection to recovery — helps patients and families plan practically and emotionally.

1. 1

   Evaluation & Eligibility

   A hematologist reviews your diagnosis, pathology, prior treatments, organ function, and fitness to confirm whether CAR T is appropriate and safe for you at this point in your cancer journey.

2. 2

   Apheresis (Cell Collection)

   Your blood is passed through a machine that separates T cells and returns the rest to you. The procedure takes a few hours and is performed at the treating center.

3. 3

   Laboratory Manufacturing

   Your collected T cells travel to a specialized lab where the CAR receptor is genetically added and the cells are multiplied into millions. This is the longest step in the process.

4. 4

   Bridging Therapy

   While your cells are being manufactured, some patients receive light treatment to keep the cancer under control and prevent progression during the manufacturing wait.

5. 5

   Lymphodepleting Chemotherapy

   A short course of chemotherapy given a few days before infusion reduces existing immune cells, creating space for the new CAR T cells to expand and work effectively.

6. 6

   CAR T Cell Infusion

   The reprogrammed T cells are infused back into you — typically as a single intravenous infusion. The treatment itself is brief, but the days that follow require close observation.

7. 7

   Post-Infusion Monitoring

   The first 1–2 weeks require close hospital-based monitoring to detect and manage cytokine release syndrome and other early side effects. Follow-up continues for 30–60 days total.

India crossed a major milestone in 2023 when it approved its first indigenous CAR T therapy, ending years in which patients had no affordable domestic option. A second approval followed in 2025, and the infrastructure continues to expand.

• 2023: A Landmark Approval

  NexCAR19 became India's first approved CAR T therapy in October 2023, developed by ImmunoACT — a company born from IIT Bombay in collaboration with Tata Memorial Centre. It brought the price to roughly one-tenth of Western levels.

• 2025: Second Globally Benchmarked Product

  Qartemi (Immuneel Therapeutics, Bengaluru), approved January 2025 and licensed from Hospital Clinic de Barcelona, is India's first globally benchmarked CAR T product — manufactured and trialed to international standards.

• Growing Access in Government Hospitals

  Government hospitals are establishing dedicated CAR T units. A Jaipur government hospital set up India's first dedicated clinical hematology department for CAR T, offering the indigenous therapy at highly subsidized rates.

• India's New Role in Global Cell Therapy

  India is no longer only a destination for affordable generic cancer drugs. With indigenous CAR T development and clinical results matching global standards, it is becoming a center of cell therapy innovation for South Asia and beyond.

India currently has two approved CAR T cell therapies, both targeting CD19. Understanding the differences helps in matching the right product to the right patient and diagnosis.

CAR T is not a first treatment — it is for patients whose blood cancer has relapsed or stopped responding to prior therapy. Eligibility is clinical, molecular, and fitness-based, and must be confirmed by a specialist after reviewing your full records.

• Relapsed / Refractory B Cell ALL

  Adolescents and adults with B cell acute lymphoblastic leukemia that has relapsed or not responded after two or more prior lines of therapy are among the clearest candidates for CAR T in India.

• Large B Cell Lymphoma (DLBCL)

  Patients with diffuse large B cell lymphoma and certain other large B cell lymphomas that have relapsed after standard treatment are a primary approved indication for both Indian CAR T products.

• Other B Cell Non-Hodgkin Lymphomas

  Qartemi's approval covers a broader range of relapsed or refractory adult B cell non-Hodgkin lymphomas. Specific eligibility depends on subtype, CD19 expression status, and prior treatment history.

• Key Eligibility Factors

  CD19-positive cancer cells, adequate organ function, acceptable performance status, no active severe infection, and sufficient fitness to tolerate the full CAR T process — including lymphodepletion and 30–60 days of close monitoring.

India has changed the affordability of CAR T more than any other country — without compromising on clinical results. Here is how costs compare globally, and what families need to know about drug price vs. total treatment cost.

The figures that define India's CAR T landscape — from approvals and response rates to cost savings and timelines.

• 2Approved CAR T Therapies in IndiaNexCAR19 (Oct 2023) and Qartemi (Jan 2025) — both CD19-directed, for B cell cancers.
• ~83%Overall Response RateReported at Day 90 in the IMAGINE trial for Qartemi; NexCAR19 showed majority response with ~50% complete remission in its trials.
• ~10×More Affordable vs USAIndia's CAR T costs ₹30–50L ($35K–$50K) compared to $400,000+ in the United States — the same clinical category at a fraction of the price.
• 4–6 wksCell Manufacturing TimeFrom apheresis to infusion typically spans 4–6 weeks, plus 30–60 days of close post-infusion monitoring near the treating center.

CAR T offers genuine hope for certain relapsed blood cancers — but it is a serious treatment with real risks and clear boundaries on who it helps today. Both sides of the picture matter for a grounded decision.

For many patients with an approved indication, India is the right answer. For others — with specific molecular targets, myeloma, or clinical trial needs — looking beyond India is reasonable. Here is how to think through the comparison honestly.

India's CAR T pipeline is moving fast. The next wave of products could open the therapy to patient groups — including myeloma and relapsed disease with antigen loss — not covered by today's two approved products.

• BCMA-Targeted Therapy for Myeloma

  Teams at AIIMS and other Indian institutions are developing BCMA-directed CAR T products for multiple myeloma — a major unmet need in India today. Clinical evaluation is expected to expand substantially in coming years.

• CD22 and Dual-Target Approaches

  Research continues on CD22-directed therapies and dual-antigen products targeting both CD19 and CD22 simultaneously — designed to reduce the risk of cancer escaping by losing a single marker.

• Solid Tumor CAR T

  Solid tumor CAR T remains an active but difficult global research frontier. Progress is slower due to inconsistent target expression and hostile tumor microenvironments. Any claims of routine solid tumor CAR T should be approached with healthy caution.

• Expanding Public Hospital Infrastructure

  Government hospitals are establishing dedicated CAR T units and subsidized programs across India. This should significantly improve access across income levels over the next several years, particularly in Tier 1 and Tier 2 cities.

A CAR T decision arrives at one of the hardest moments in a cancer journey — often after other treatments have stopped working. CancerFax is a patient navigation platform, not a hospital, built to help you see clearly and move forward with confidence.

• Medical Report Review

  We help make sense of your diagnosis, pathology, molecular findings, and treatment history — and flag missing tests that may affect CAR T eligibility before you commit to a center.

• Second Opinion Coordination

  We connect patients with experienced hematologists and cell therapy specialists for a clinical review of whether CAR T is appropriate and at which point in the treatment journey.

• Hospital & Center Matching

  We align your diagnosis with centers that have genuine CAR T experience — not just brand recognition, but the right team, monitoring protocols, ICU backup, and post-infusion follow-up program.

• India vs International Comparison

  Where a needed therapy, target, or clinical trial is not yet available in India, we help you understand and compare cross-border options — including established centers in China and elsewhere — side by side.

20 in-depth guides covering every aspect of CAR T therapy — from eligibility and the treatment process to cost comparisons, disease-specific evidence, India vs international options, and beyond.

Frequently Asked Questions

The most common questions from patients and families exploring CAR T cell therapy in India — answered clearly and honestly.